Description
Recombinant monoclonal antibody to CD8 alpha/Lyt-2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma YTS 169.4. This is a chimeric antibody created to reduce immunogenicity during in vivo applications.
Target
CD8 alpha/Lyt-2
Target Alias Names
Leu2, CD8, CD8A, CD8a molecule, CD8a antigen, Leu2 T-lymphocyte antigen, Lyt-2, Lyt2OKT8, p32T-cell antigen Leu2, T-cell antigen, T cell co-receptor, T-cell surface glycoprotein CD8 alpha chain, T-cell surface glycoprotein Lyt-2, T8 T-cell antigen
Isotype/Mimetic
IgG2b
Animal-Derived Biomaterials Used
No
Sequence Available
No
Original Discovery Method
recombinantly reformatted hybridoma (from pre-2020 immunisation)
Original Discovery Information Provided On Datasheet
Yes
Antibody/Binder Origins
Animal-dependent discovery (in vitro display, OR immunisation pre-2020), In vitro recombinant expression